Amgen: Psoriasis trials

The registry lists 53 Psoriasis studies with Amgen as lead sponsor. 0 are open to participants now and 31 have results posted.

Phase 1 2Phase 2 8Phase 3 24Phase 4 9No phase 10(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)CompletedNCT05174065Phase 3Results posted
• A Comparative Study Between ABP 501 and Humira® in Participants With Moderate to Severe Plaque PsoriasisCompletedNCT05073315Phase 3Results posted
• A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04761627Phase 3Results posted
• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04607980Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar PustulosisCompletedNCT04057937Phase 2Results posted
• A Phase 3B, Open-label, Single-arm Study of the Efficacy and Safety of Apremilast, in Subjects With Plaque Psoriasis That is Not Adequately Controlled by Topical TherapyCompletedNCT03930186Phase 3Results posted
• An Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Genital PsoriasisCompletedNCT03777436Phase 3Results posted
• A Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Adults With Manifestations of Plaque Psoriasis and Impaired Quality of LifeCompletedNCT03774875Phase 4Results posted
• Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and EfficacyCompletedNCT03721172Phase 3Results posted
• Efficacy and Safety Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisCompletedNCT03701763Phase 3Results posted
• A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the ScalpCompletedNCT03123471Phase 3Results posted
• A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT02576678Phase 2Results posted
• A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis.CompletedNCT02425826Phase 4Results posted
• Study to Assess the Immunogenicity and Safety of Etanercept Produced Using a Modified Process in Patients With Plaque PsoriasisCompletedNCT02274792Phase 4Results posted
• Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type PsoriasisCompletedNCT01988103Phase 2Results posted
• Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque PsoriasisCompletedNCT01970488Phase 3Results posted
• Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With EtanerceptCompletedNCT01875991Phase 4Results posted
• Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque PsoriasisCompletedNCT01690299Phase 3Results posted
• Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to AdalimumabTerminatedNCT01543204Phase 4Results posted
• Efficacy and Safety of Etanercept 50 mg Once Weekly Plus As Needed Topical Agent in Moderate to Severe Plaque PsoriasisCompletedNCT01313221Phase 3Results posted
• Evaluate Efficacy, and Safety of Topical Therapy and Etanercept in Subjects With Moderate to Severe Plaque PsoriasisCompletedNCT01235442Phase 3Results posted
• Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.CompletedNCT01232283Phase 3Results posted
• Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque PsoriasisCompletedNCT01194219Phase 3Results posted
• The Efficacy and Safety of Adding Methotrexate to Etanercept in PsoriasisCompletedNCT01001208Phase 3Results posted
• Moderate to Severe Plaque Psoriasis With Scalp InvolvementCompletedNCT00791765Phase 4Results posted
• Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)CompletedNCT00773734Phase 2Results posted
• Apremilast Safety and PK Study in Recalcitrant Plaque PsoriasisCompletedNCT00521339Phase 2Results posted
• Canadian Assessment of Patient Outcomes and Effectiveness of Etanercept (Enbrel) in PsoriasisCompletedNCT00332332Phase 4Results posted
• Observational Safety Study of Etanercept (Enbrel) for Treatment of PsoriasisCompletedNCT00322439Results posted
• Pediatric Open-Label Extension Study of Etanercept in Patients With Plaque PsoriasisCompletedNCT00141921Phase 3Results posted
• Etanercept (Enbrel®) in Psoriasis - PediatricsCompletedNCT00078819Phase 3Results posted
• A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque PsoriasisCompletedNCT04175613Phase 3
• A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical PracticeCompletedNCT04031027
• A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in FranceCompletedNCT03757013
• Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in SpainCompletedNCT03539419
• Post-Marketing Surveillance Study of OTEZLACompletedNCT03284879
• A Study of the Real-life Management of Psoriasis Patients Treated With Otezla® (Apremilast) in BelgiumCompletedNCT03097003
• APremilast After FumaRic Acid Ester TreatmentCompletedNCT02954081
• A Study of Real-World Experience of Psoriasis Patients Treated With Apremilast in Clinical Dermatology PracticeCompletedNCT02740218
• Observational Study of Apremilast in Patients With Psoriasis in The NetherlandsCompletedNCT02652494
• A Study of Otezla® in Patients With Plaque Psoriasis Under Routine ConditionsCompletedNCT02626793
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 811 in Subjects With PsoriasisCompletedNCT01510951Phase 1
• Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of AMG 557 in Adults With PsoriasisTerminatedNCT01493518Phase 1
• Double-Blind, Randomized, Placebo-controlled Comparison of CC-10004 in Subjects With Moderate to Severe Plaque Type PsoriasisCompletedNCT00606450Phase 2
• Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type PsoriasisCompletedNCT00604682Phase 2
• AMG 714 20060349 Multiple Dose Study in Moderate to Severe Psoriasis SubjectsCompletedNCT00443326Phase 2
• Double-blind, Randomized, Placebo-controlled Phase 3 Study of Etanercept in the Treatment of Psoriatic Arthritis and PsoriasisCompletedNCT00317499Phase 3
• Study of Etanercept in the Treatment of Psoriasis in Adult SubjectsCompletedNCT00121615Phase 3
• Evaluating the Safety of Etanercept 50 mg Twice Weekly in Subjects With PsoriasisCompletedNCT00111449Phase 3
• Evaluating the Safety of Etanercept in the Treatment of Psoriasis in Adult SubjectsCompletedNCT00111436Phase 3
• Enbrel® in Psoriatic ArthritisCompletedNCT00111124Phase 4
• An Evaluation of Etanercept in the Treatment of Subjects With PsoriasisCompletedNCT00111111Phase 3
• Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of PsoriasisCompletedNCT00110981Phase 4